BioCryst is profitable. Now it wants to buy more rare disease drugs
CNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our journalism to elevate stories…
FDA approves Gilead HIV pill Bixlenvo designed to simplify treatment
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that…
The startup using AI to help build custom treatments for rare diseases
Jacalyn Lee, founder of The DAND Alliance, and her youngest daughter Isla. Jacalyn Lee CNBC Cures is proudly…
AstraZeneca stock dives 9% after heart drug trial misses target
Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease failed…
Weight loss drug maker stock sinks 25% as safety data spooks investors
Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data…
Stock market today: Live updates
Traders work on the floor of the New York Stock Exchange. NYSE Futures linked to the S&P 500…
Novartis CEO: Reality of Trump’s drug pricing to set in over next 18 months
Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult…
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most…
Stocks making the biggest moves midday: KKR, BX, CRWD, IP
Check out the companies making the biggest moves midday: Financials — The financials sector of the S &…
Gilead to acquire cancer therapy developer Arcellx
A Gilead Sciences office is shown in Foster City, California, U.S. May 1, 2018. Stephen Lam | Reuters…